IncellDx Announces Successful Presentation of Complete Solution for Cervical Cancer Screening at International HPV Meeting

IncellDx’s HPV OncoTect® E6/E7 mRNA Kit Greatly Increases Specificity Compared to Other HPV tests and was Successfully Used in a Large Clinical Trial in Women Under 30 Years of Age.

MENLO PARK, Calif.--(BUSINESS WIRE)-- IncellDx, Inc., a sponsor at the International HPV meeting this week in Montreal, Canada, announces that two presentations at the meeting demonstrated that IncellDx’s HPV OncoTect® E6/E7 mRNA kit greatly increases specificity compared to other HPV tests and was successfully used in a large clinical trial in women under 30 years of age.

Data on over 3000 women was presented by Hunter Laboratories, Campbell CA showing that the performance of this E6/E7 mRNA technology in women under 30 years old was equally as sensitive and more specific than other HPV tests in women greater than 30 years old. “Because cancer causing types of HPV transiently infect women in their twenties, tests like HPV OncoTect®, that detect whether the virus is expressing the genes that cause cancer are necessary for cervical cancer screening in this age group,” said Chris Riedel, CEO of Hunter Laboratories.

The second presentation by investigators from Stanford University and Madrid, Spain demonstrated that HPV OncoTect® has significantly increased specificity for pre-cancerous and cancerous conditions of the cervix than other commercially available tests. The investigators also presented data showing high sensitivity and specificity for pre-cancerous conditions of the anus in men, a cancer also caused by HPV.

The HPV OncoTect® technology measures the quantity of overexpression of E6/E7 mRNA, the cancer causing genes of HPV, in each cell and the total proportion of cells that are overexpressing E6/E7 mRNA. This information has the promise of providing more specific indication that an HPV infection is transforming into cervical cancer. The HPV OncoTect® can be performed directly from routine liquid based cytology samples and provides results in 3 ½ hours. The HPV OncoTect® test is currently CE-IVD marked and available in Europe, South America, and Southeast Asia.

About IncellDx, Inc.

IncellDx, Inc. is a privately held company located in the heart of the Silicon Valley in Menlo Park, California. IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, HIV/AIDS, hepatitis, and organ transplant rejection.



CONTACT:

IncellDx, Inc.
Eric Hass, 650-777-7630

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Clinical Trials  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.